Pharmacologically Triggered Migraine Without Aura and Neuroimaging
Migraine is a highly disabling disorder affecting 14% of the general population Worldwide and ranked as the 6th most debilitating disease worldwide by the WHO. One of the most fundamental questions of migraine, which remains to be elucidated, is the mechanism behind the generation of migraine attacks.
We will use calcitonin gene-related peptide (CGRP) and sildenafil as pharmacological triggers of migraine, combined with advanced neuroimaging techniques, to investigate the attack initiating pathophysiology.
Both substances have previously been administered to healthy participants and migraine without aura patients, inducing headache and migraine-like-attacks.
We hope to contribute with novelty to the current understanding of the migraine pathophysiology and development of more efficient treatment of migraine.
|Migraine With Aura||Drug: Calcitonin Gene-Related Peptide Drug: Sildenafil Drug: Placebo|
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Double BlindPrimary Purpose: Basic Science
- CGRP and sildenafil induced MRI-changes [ Time Frame: 0-6h ]CGRP and sildenafil induced MRI-changes
|Actual Study Start Date:||August 2016|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||December 2018 (Final data collection date for primary outcome measure)|
|Experimental: CGRP||Drug: Calcitonin Gene-Related Peptide|
|Experimental: Sildenafil||Drug: Sildenafil|
|Placebo Comparator: Placebo||Drug: Placebo|
Please refer to this study by its ClinicalTrials.gov identifier: NCT03143465
|Contact: Samaira Younisfirstname.lastname@example.org|
|Danish Headache Center, University Hospital||Recruiting|
|Contact: Samaira Younis|